Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990) board approved the proposed full circulation of up to nearly 3.6 million domestic shares and over 4.6 million unlisted foreign shares, a Friday Hong Kong bourse filing said.
Shares of the drug company were up 2% in Monday afternoon trading.
The firm, on the same day, submitted the relevant filing application to the China Securities Regulatory Commission.
The company said it will make further announcements as and when needed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.